In regards to surgery it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10 - 30 % of all cases , and systematic limphadenectomy , necessary to be able to obtain an adequate surgical staging .
Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer .
Radiotherapy can be used to palliate symptoms .
In the present , there is not a st and ardized screening method .
Diagnosis in early stages means a better survival .
Radiotherapy can be indicated to palliate symptoms
INTRODUCTION Ovarian cancer ( OC ) is the third most common gynecologic malignancy worldwide .
Most of cases it is of epithelial origin .
At the present time there is not a st and ardized screening method , which makes difficult the early diagnosis .
The 5-year survival is 90 % for early stages , however most cases present at advanced stages , which have a 5-year survival of only 5 - 20 % .
GICOM collaborative group , under the auspice of different institutions , have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia .
Until now , laparoscopy for diagnostic-staging surgery is not well known as a recommended method .
In advanced stages , primary cytoreduction is recommended as initial treatment .
Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer
Many patients with advanced ovarian cancer will develop recurrent disease . For those patients who have recurrence of disease at least 6 months after initial therapy , the paclitaxel – platinum combination has been shown to be a superior treatment to platinum monotherapy . However , many patients develop clinical ly relevant neurotoxicity , frequently result ing in treatment discontinuation . The efficacy and safety of an alternative regimen that does not show significant neurotoxicity were evaluated by comparing gemcitabine – carboplatin with carboplatin in platinum-sensitive recurrent ovarian cancer patients in a Gynecologic Cancer InterGroup trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group , the National Cancer Institute of Canada Clinical Trials Group , and the European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group . Participants with recurrent platinum-sensitive ovarian cancer were r and omly assigned to receive either gemcitabine – carboplatin or carboplatin every 21 days . The primary objective was to compare progression-free survival ( PFS ) between the groups . From September 1999 to April 2002 , 356 patients ( 178 participants received gemcitabine – carboplatin , 178 received carboplatin only ) were r and omized to treatment . Patients received six cycles of either gemcitabine – carboplatin or carboplatin . With a median follow-up of 17 months , median PFS was 8.6 months for gemcitabine – carboplatin ( 95 % confidence interval [ CI ] 7.9–9.7 months ) and 5.8 months for carboplatin ( 95 % CI 5.2–7.1 months ; hazard ratio [ HR ] 0.72 [ 95 % CI 0.58–0.90 ; P = 0.0032 ] ) . The response rate for the gemcitabine – carboplatin group was 47.2 % ( 95 % CI 39.9–54.5 % ) and 30.9 % for carboplatin group ( 95 % CI 24.1–37.7 % ; P = 0.0016 ) . The HR for overall survival was 0.96 ( 95 % CI 0.75–1.23 ; P = 0.7349 ) . Patients treated with gemcitabine – carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life .  Gemcitabine – carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer
In regards to surgery it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10 - 30 % of all cases , and systematic limphadenectomy , necessary to be able to obtain an adequate surgical staging .
Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer .
Radiotherapy can be used to palliate symptoms .
In the present , there is not a st and ardized screening method .
Diagnosis in early stages means a better survival .
Radiotherapy can be indicated to palliate symptoms
INTRODUCTION Ovarian cancer ( OC ) is the third most common gynecologic malignancy worldwide .
Most of cases it is of epithelial origin .
At the present time there is not a st and ardized screening method , which makes difficult the early diagnosis .
The 5-year survival is 90 % for early stages , however most cases present at advanced stages , which have a 5-year survival of only 5 - 20 % .
GICOM collaborative group , under the auspice of different institutions , have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia .
Until now , laparoscopy for diagnostic-staging surgery is not well known as a recommended method .
In advanced stages , primary cytoreduction is recommended as initial treatment .